NCT06833190: An ongoing trial by Regeneron Pharmaceuticals
This trial is ongoing. It must report results 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06833190 |
|---|---|
| Title | A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Multiple Dose Regimen of REGN5381, an NPR1 Monoclonal Antibody Agonist, in Participants With Uncontrolled Hypertension |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 16, 2025 |
| Completion date | Oct. 15, 2025 |
| Required reporting date | Oct. 15, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |